Journals / Anatomy / 2015 / Cilt: 9 - Sayı: 3

OPTOGENETIC STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES

Journal
Anatomy
Pages
177–181
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Because experiments conducted with conventional CR are not suitable for testing chronic long-term studies, there is a certain need for a controlled medium for optogenetic neurodegenerative disease experiments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Optogenetic tools and strategies, as an innovative approach to control neurodegenerative diseases, have been developed in recent years with the application of a combination of optical and genetic techniques on a certain group of cells of living tissue.
📊
Key Findings & Data:Strategies for suppressing neurons are based on activation of light-sensitive prokaryotic membrane proteins that act as ion channels and transporters.
💡
Conclusion & Impact:Because experiments conducted with conventional CR are not suitable for testing chronic long-term studies, there is a certain need for a controlled medium for optogenetic neurodegenerative disease experiments.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Alzheimer’s disease · neurodegenerative diseases · optogenetics

Abstract

Optogenetic tools and strategies, as an innovative approach to control neurodegenerative diseases, have been developed in recent years with the application of a combination of optical and genetic techniques on a certain group of cells of living tissue. With this technique, a particular cell type and their predefined pathway can be controlled precisely. The basic steps of this optogenetics include discovery and placing of light-sensitive molecules into cells to provide optical control and applications in animal experiments. Strategies for suppressing neurons are based on activation of light-sensitive prokaryotic membrane proteins that act as ion channels and transporters. Optogenetic strategies that are adapted clinically have the capacity to provide temporal, regional and cellular specific delivery in ways that no other treatment may suggest. Engineering channelrhodopsin(CR) molecule and its expression are very important in terms of optogenetic experiments. Because experiments conducted with conventional CR are not suitable for testing chronic long-term studies, there is a certain need for a controlled medium for optogenetic neurodegenerative disease experiments.

🔖

Cite This Article

SOKULLU, Ş. E. (2015). OPTOGENETIC STRATEGIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES. Anatomy, Cilt: 9 - Sayı: 3, 177–181. https://ajindex.com/articles/184094

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Boyden ES, Zhang F, Bamberg E, Nagel G, Deisseroth K. Millisecond- timescale, genetically targeted optical control of neural activity. Nat Neurosci 2005;8:1263–8.
  2. Nagel G, Szellas T, Huhn W, Kateriya S, Adeishvili N, Berthold P, Ollig D, Hegemann P, Bamberg E. Channelrhodopsin-2, a directly light-gated cation-selective membrane channel. Proc Natl Acad Sci U S A 2003;100:13940–5. Lin JY. A user’s guide to channelrhodopsin variants: features, limitations and future developments. Exp Physiol 2011;6:19–25.
  3. Gradinaru V, Thompson KR, Zhang F, Mogri M, Kay K, Schneider MB, Deisseroth K. Targeting and readout strategies for fast optical neural control in vitro and in vivo. J Neurosci 2007;27:14231–8.
  4. Lin JY, Lin MZ, Steinbach P, Tsien RY. Characterization of engineered channelrhodopsin variants with improved properties and kinetics. Biophys J 2009;96:1803–14.
  5. Gunaydin LA, Yizhar O, Berndt A, Sohal VS, Deisseroth K, Hegemann P. Ultrafast optogenetic control. Nat Neurosci 2010;13:387–92.
  6. Berndt A, Schoenenberger P, Mattis J, Tye KM, Deisseroth K, Hegemann P, Oertner TG. High-efficiency channelrhodopsins for fast neuronal stimulation at low light levels. Proc Natl Acad Sci USA 2011;108:7595–600.
  7. Zhang F, Prigge M, Beyriere F, Tsunoda SP, Mattis J, Yizhar O, Hegemann, P, Deisseroth K. Red-shifted optogenetic excitation: a tool for fast neural control derived from Volvox carteri. Nat Neurosci 2008;11:631–3.
  8. Govorunova EG, Spudich EN, Lane CE, Sineshchekov OA, Spudich JL. New channelrhodopsin with a red-shifted spectrum and rapid kinetics from Mesostigma viride. MBio 2011;2:e00115–11. Yizhar O, Fenno LE, Prigge M, Schneider F, Davidson TJ, O'Shea DJ, Sohal VS, Goshen I, Finkelstein J, Paz JT, Stehfest K, Fudim R, Ramakrishnan C, Huguenard JR, Hegemann P, Deisseroth K. Neocortical excitation/inhibition balance in information processing and social dysfunction. Nature 2011;477:171–8.
  9. Schobert B, Lanyi JK. Halorhodopsin is a light-driven chloride pump. J Biol Chem 1982;257:10306–13.
  10. Zhang F, Wang LP, Brauner M, Liewald JF, Kay K, Watzke N, Wood PG, Bamberg E, Nagel G, Gottschalk A, Deisseroth K. Multimodal fast optical interrogation of neural circuitry. Nature 2007;446:633–9.
  11. Gradinaru V, Thompson KR, Zhang F, Mogri M, Kay K, Schneider MB, Deisseroth K. Targeting and readout strategies for fast optical neural control in vitro and in vivo. J Neurosci 2007;27: 14231–8.
  12. Gradinaru V, Zhang F, Ramakrishnan C, Mattis J, Prakash R, Diester I, Goshen I, Thompson KR, Deisseroth K. M